All In MedTech

Device Trial Radar · NCT02844465

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

Stereotactic Laser Ablation for Temporal Lobe Epilepsy

Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

167

Actual

Start

Dec 2016

Primary completion

Dec 11, 2023

Study completion Dec 11, 2023

Sponsor

Lead sponsor
MedtronicNeuroNot on our public-company list
Sponsor type
Industry
First posted
Jul 26, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

Conditions

  • Temporal Lobe Epilepsy

Interventions

  • Visualase MRI-Guided Laser AblationDevice

    All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Qualifying Adverse EventsTime frame: 12 months
  2. Seizure Freedom, Defined as Engel Classification of Postoperative Outcome Class ITime frame: 12 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Stanford University

    Palo Alto, California

  • University of California, San Francisco

    San Francisco, California

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.